The Cambridge Angels are a group of high-net worth investors who have proven experience as successful entrepreneurs in internet, software, technology and bio-technology. Members invest in and mentor high quality start-up and early-stage companies in these sectors in the Cambridge (UK) area and throughout the UK. Typical funding requirements that the Cambridge Angels meet are in the range of £50,000 to £500,000 - although it is worth noting that several of their portfolio companies have received more than £1m in funding from their Members over several funding rounds. Their Members have been responsible for a large number of the “Cambridge Phenomenon” success stories over recent years. Therefore, in addition to providing funding for early-stage companies, the Cambridge Angels also offer start-ups the considerable benefit of a wide range of expertise, contacts and directly relevant experience in establishing and growing entrepreneurial businesses successfully.

Cambridge Angels group

Connect is the Product VC. We are a thesis-led, pan-European pre-seed and seed stage VC. We invest in opinionated products, crafted with love, and loved by many.

Connect Ventures

Samos Investments is a private equity investor with a focus on high-growth European businesses.  Samos invests across a range of sectors including digital media, e-commerce, retail, financial services, energy and natural resources.  Samos takes a proactive approach with its portfolio companies, working alongside many of the US and Europe’s top venture funds, family offices and private investors.  The Samos Partners are also active angel/seed investors.

Samos Investments

Entrepreneur First is the place where the ambitious come together to build globally important technology companies. Through our platform running in 6 cities across 3 continents, we invest in high-potential individuals to help them meet their co-founder, develop their ideas and secure funding from leading investors in the shortest possible time.   We have built over 300 companies from scratch; have over 5000 alumni worldwide; and our portfolio is valued at over $5bn. EF companies include Tractable (Computer Vision, currently valued at $1bn as of June 2021), Magic Pony Technology (AI, acquired by Twitter for a reported $150m), Represent (social commerce, acquired by CustomInk), BloomsburyAI (acquired by Facebook), Cleo (fintech), OpenCosmos (space), CloudNC (manufacturing), Transcelestial (satellite communications) and many more. We're backed by some of the world's best tech founders and investors, including Reid Hoffman (LinkedIn), Greylock Partners, Founders Fund, Demis Hassabis (Google Deepmind) and Taavet Hinrikus (Wise). For more information about Entrepreneur First, visit www.joinef.com.

Entrepreneur First

Walking Ventures is a seed fund which invests in early-stage Internet and other technology startups based in Europe.  The fund is a private vehicle controlled by Tim Jackson, a leading figure in the European technology scene as a venture capitalist, entrepreneur, angel investor, commentator and technology journalist.

Walking Ventures

Isomer's entrepreneurial approach accesses high-potential opportunities through limited partner investments in funds, company co-investments, and providing liquidity to firms and founders via secondary purchases.

Isomer Capital

Pareto Holdings is an early-stage investment vehicle founded by Jon Oringer and Edward Lando. We execute on dozens of investments per month and are often the first to back exceptional entrepreneurs. We are industry and geography agnostic, and specialize in pre-seeding companies. We’ve made 500+ investments to date. Unlike others, we only invest our own money with a small and mighty team around the world.

Pareto Holdings

Next generation early stage tech investing, bridging Europe and the USA. 7percent Ventures invest in early stage tech startups which represent billion dollar opportunities.  They are not interested in startups which iterate a market, they are interested in startups that transform them. Change is the prerequisite of disruption. To monopolize a market they believe you must fundamentally disrupt it. To do that, you must have a product which solves a painful problem in a better way than existing solutions or serves a need that is not currently being satisfied. They are sector agnostic, although they do not invest in areas that they do not understand or where they cannot add value.  They will not invest in any business –however good it might be—which is not a billion dollar opportunity.  Your startup must doing something which is scalable enough in a large enough market for a future valuation of $1bn to be possible.

7percent Ventures

Atomico is an international investment firm that focuses on helping disruptive technology companies scale globally. It partners with technology founders at the Seed stage and beyond with a particular focus on Europe, leveraging deep operational experience to supercharge their growth. The company's team of founders, investors, and operational leaders have been responsible for global expansion, hiring, and marketing at companies from Skype, Google, and Twitter to Wise and Snowflake. It specializes in seed, startup, Series A, early venture, mid venture, late venture, emerging growth, and growth capital investments.   Atomico was founded in 2006 and is headquartered in London, England, with offices in Paris, Berlin, and Stockholm

Atomico

Greycroft is a venture capital firm that focuses on technology start-ups and investments in the Internet and mobile markets. With offices in two of the most important business hubs in the world, New York and Los Angeles Greycroft uniquely positioned to serve entrepreneurs who have chosen us as their partners. The firm leverages an extensive network of media and technology industry connections to help entrepreneurs gain visibility, build strategic relationships, bring their products to market, and build successful businesses.  Greycroft manages in excess of $1 billion and has made over 200 investments since its inception in leading companies including Acorns, App Annie, Bird, Botkeeper, Bright Health, Boxed, Braintree, Buddy Media, Everything But The House, Extreme Reach, Huffington Post, Icertis, JW Player, Maker Studios, Plated, Scopely, Shipt, TheRealReal, Thrive Market, Trunk Club, Venmo, WideOrbit, and Yeahka. Greycroft has adopted the Diversity Term Sheet Rider.

Greycroft

Hoxton Ventures focuses on startups that either disrupt existing industries or invent entirely new market categories. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed, and Series A stage companies, and follows its capital through the life of the company.  The firm is based in London and invests all across Europe.

Hoxton Ventures

Exor Ventures is the venture capital arm of Exor, one of Europe's largest diversified holding companies. Exor Ventures focuses on early and growth-stage investments in technology-driven companies across various sectors, including digital services, fintech, cybersecurity, and mobility. Exor Ventures leverages its strategic insights and global network to identify promising startups with disruptive potential and supports them through funding, mentorship, and access to its extensive resources.   EXOR Seeds offers a truly different type of partnership to the select group of entrepreneurs that it backs: - As a fifth-generation family-led business, we proved that we are builders not traders; - Our permanent capital allows us to take a long-term view and put the interest of the companies We invest in first; - Our global network, across industries and geographies, is a unique advantage to entrepreneurs

Exor Ventures

We have a vision for the future in which data, computing, networks, and other digital and deep technologies deliver meaningful outcomes and insight for improving health and the provision of care. We believe the creation of new businesses is built on in-depth understanding of the complex network of healthcare system participants, and marrying that with meaningful engineering innovation, advanced data science, and information technology-enabled products and services. We look for and seed founders determined to effectively and efficiently serve these participants on the european continent and internationally. We are committed to addressing needs across the care continuum, healthcare systems, and all specialties.

Nina Capital

We're Acequia Capital, a team and partnership with roots in Albuquerque. We're knowledge workers and systems thinkers who love to keep good company in most fields.

Acequia Capital (AceCap)

Kheiron

At Kheiron, we are going where only a few have gone before; seeking a new understanding of cancer and how to detect it using artificial intelligence and human insight. We’ve made significant breakthroughs with our breast cancer screening product Mia but this is just the beginning of our journey. Ultimately we want to radically improve the outcomes for cancer patients by pioneering a new era of, what we call, precision radiology. While this all sounds very serious and it is, we believe in having fun along the way. Karaoke is our favourite sport. We also have an incredible crew from more than twenty different countries and offices in London, Budapest, Amsterdam and San Francisco.  Giving every woman a better fighting chance against cancer.

Kheiron Medical Technologies is an applied science company developing AI solutions to support cancer diagnostics, starting with breast cancer screening. Their flagship product, Mia, is an AI breast screening software designed to assist radiologists in making accurate and timely screening decisions. Mia fully de-identifies patient data before analyzing the mammogram on Microsoft's Azure Cloud platform and providing a recommendation on whether a woman should be recalled for further assessment.

Kheiron Medical Technologies and Microsoft Join Forces To Support Breast Cancer Detection

Kheiron Medical Technologies Named to Fast Company's Annual List of the World's 50 Most Innovative Companies for 2022

Gateshead Health Foundation NHS Trust furthers its partnership with Kheiron Medical Technologies under the NHS AI in Health & Care Award

Kheiron Medical Technologies

Automation in clinical diagnostics to improve speed and accuracy in patient diagnosis and treatment.

Clinical Decision Support Systems

Stanford University Partners with Kheiron Medical Technologies to Pioneer Use of AI in New Areas of Oncology

Kheiron Medical Technologies is an applied science company developing AI solutions to support cancer diagnostics, starting with breast cancer screening. Their flagship product, Mia, is an AI breast screening software designed to assist radiologists in making accurate and timely screening decisions. Mia fully de-identifies patient data before analyzing the mammogram on Microsoft's Azure Cloud platform and providing a recommendation on whether a woman should be recalled for further assessment.
Mia aims to empower radiologists by reducing their workload, increasing screening efficiency, and improving the patient experience. The company has conducted unprecedented large-scale global clinical studies to validate Mia's performance on diverse populations, ensuring it can work effectively on any woman, regardless of ethnicity, mammography device, or screening workflow.
In November 2022, Kheiron announced a technology collaboration with Microsoft, leveraging Azure Cloud's scale to enable global reach and impact of Mia. The solution is currently deployed at four sites in Europe, with further deployments underway at 15 NHS sites in the UK as part of a 3-year project awarded by NHS England in 2020 to deploy Mia at scale. Upon completion, this project will result in over half a million women annually being screened by Mia in the UK.

<div>
 
 Clover Health is a healthcare company focused on serving Medicare Advantage members. The company leverages its proprietary software platform, the Clover Assistant, to aggregate and analyze patient data from across the healthcare ecosystem. This data-driven approach aims to support clinical decision-making and improve health outcomes for seniors.
 
 
 
 
 Clover Health operates in two segments: Insurance and Non-Insurance. Through its Insurance segment, the company provides PPO and HMO plans to Medicare Advantage members across several states. As of March 2022, Clover Health had approximately 257,000 lives under its management, a significant increase from around 66,000 lives in the first quarter of 2021.
 
 
 
 
 The Clover Assistant is a key component of Clover Health's strategy. This software platform is designed to provide physicians with relevant patient information to facilitate coordinated care. The company reported that in 2021, its Insurance members whose primary care providers (PCPs) utilized the Clover Assistant had a significantly lower medical care ratio (MCR) compared to members whose PCPs did not use the platform.
 
 
 
 
 In its Non-Insurance segment, Clover Health participates in the Centers for Medicare &amp; Medicaid Services' (CMS) Direct Contracting model, which will transition to the ACO Reach model in 2023. This segment involves aligning with Original Medicare beneficiaries through provider attribution or voluntary alignment.
 
 
 
 
 For the full year 2022, Clover Health expected total revenues to range from USD 3.0 billion to USD 3.4 billion, including projected Insurance revenue of USD 1.0 billion to USD 1.1 billion and Non-Insurance revenue of USD 2.0 billion to USD 2.3 billion. The company also anticipated an improvement in its Insurance MCR, falling within the range of 95% to 99%, driven by operational efficiencies, increased risk scores, and lower Covid-19 costs.
 
 
 
</div>

Clover Health

Digital Diagnostics is a healthcare technology company that develops artificial intelligence (AI) systems for disease diagnosis by analyzing medical images. The company's flagship product, LumineticsCore (formerly known as IDx-DR), is an FDA-cleared autonomous AI system designed to detect diabetic retinopathy and diabetic macular edema during a patient encounter without needing a physician to interpret the images. LumineticsCore increases patient access to care by providing diagnostic results at the point-of-care, eliminating the need for an additional appointment for most patients. This enables healthcare providers to close the gap in eye exams for diabetes care by offering a specialty-level diagnostic exam where the patient receives care.
Digital Diagnostics has also developed DermSpot, an AI system for detecting certain types of skin cancer, which is currently for investigational use only. The company aims to create AI diagnostic solutions that improve patient outcomes, increase healthcare productivity, and enhance accessibility and affordability of care. In April 2023, Digital Diagnostics expanded LumineticsCore to Labcorp patient service centers in Alabama.
Key customers and partnerships
In 2022, Digital Diagnostics signed a long-term strategic partnership with Baxter International to help front-line care providers deliver high-quality care and improve outcomes. The company also partnered with ArchWell Health to bring LumineticsCore to ArchWell Health centers across the US.
Additionally, Digital Diagnostics entered into a memorandum of understanding with the Kingdom of Saudi Arabia's Ministry of Investment in 2022 for international expansion.

Digital Diagnostics

Lunit is a leading provider of AI-powered solutions for cancer diagnostics and therapeutics. The company's flagship product, Lunit INSIGHT, is a suite of AI solutions for radiology that has been approved for commercial use in Europe and the UK through the MDR CE and UKCA certifications obtained in November 2022. The suite includes Lunit INSIGHT CXR for chest X-ray analysis and Lunit INSIGHT MMG for mammography analysis. Lunit INSIGHT CXR can detect 10 chest abnormalities, including pulmonary nodules and pneumothorax, with 97-99% accuracy, while Lunit INSIGHT MMG detects breast cancer with 96% accuracy.
After receiving FDA clearance, Lunit's solutions are clinically used in approximately 3,000 hospitals and medical institutions across 40 countries as of March 2024. In April 2024, a study published in European Radiology demonstrated that Lunit INSIGHT MMG could potentially reduce radiologists' workload by nearly 70% and boost cancer detection accuracy by 30.5%, showcasing its ability to enhance operational efficiency and improve patient outcomes.
In May 2024, Lunit completed the acquisition of Volpara Health Technologies, a New Zealand-based company offering software for early cancer detection, for USD 193 million. The acquisition aimed to strengthen Lunit's presence in the US market and leverage Volpara's robust repository of over 100 million medical images to develop innovative solutions for cancer diagnostics.
Key customers and partnerships
Lunit has established strategic partnerships to expand its reach and integrate its AI solutions into healthcare systems worldwide. In March 2024, the company signed supply contracts with Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore to provide Lunit INSIGHT CXR and Lunit INSIGHT MMG, respectively. These collaborations aimed to enhance lung and breast cancer detection in the East and Southeast Asian regions.
In November 2023, Lunit partnered with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore's public healthcare system through the AimSG platform, a national medical imaging AI initiative. The solution was piloted at Singapore General Hospital and Changi General Hospital, two major public hospitals, to enhance the efficiency of chest screening and provide innovative medical services with improved accuracy.
Lunit has also collaborated with leading healthcare technology companies, such as GE healthcare, Fujifilm, Philips, and Guardant Health, to deploy its AI products and leverage their distribution networks.

Lunit

Lumeon is a digital health company that provides a cloud-based Care Orchestration platform designed to automate and streamline the care coordination process for healthcare providers. The platform leverages real-time, bi-directional data integration and applies dynamic clinical intelligence to ensure that patients receive the right care at the right time, every time.
Lumeon's Care Orchestration platform acts as a "care traffic control" center, synchronizing disparate data across the care continuum, orchestrating and automating care pathway activities, and delivering relevant information to care teams and patients. By automating routine tasks and workflows, the platform enables care teams to focus on providing direct patient care, working at the top of their licenses.
The platform integrates with electronic health records (EHRs) and other systems, creating a real-time synthetic patient record to inform care decisions. It visualizes care plans, virtualizes monitoring, and automates routine tasks, ultimately reducing manual intervention and associated costs for providers. The platform can be deployed enterprise-wide and applied across various use cases within a healthcare system.
Key features of Lumeon's Care Orchestration platform include real-time bi-directional data integration with EHRs and other systems, automation of care orchestration tasks and workflows, and the ability to present information through multiple modalities, including within EHRs, native interfaces, web portals, and mobile apps.
Lumeon's platform has been deployed by leading healthcare providers in the US and Europe across more than 2,000 care locations, delivering measurable results in as little as 90 days.

Lumeon

Proscia is a software company that develops digital and computational pathology solutions. Its flagship product, Concentriq, is an enterprise pathology platform that serves as a hub for digital pathology data and AI applications. Concentriq bridges the gap between anatomic pathology laboratories and life sciences organizations, enabling real-world pathology data to fuel innovation that enhances patient care.
The platform delivers an open environment to run a range of AI applications, including Proscia's proprietary algorithms and those developed by partners or customers. One such AI solution is DermAI, a dermatopathology module launched in June 2019 to assist laboratories in tasks like case prioritization, automated quality assurance, and enhanced technical component reporting.
In February 2024, Proscia received 510(k) clearance from the FDA for its Concentriq AP-Dx solution for primary diagnosis in clinical settings. This comprehensive diagnostic software streamlines collaboration and helps drive confidence and efficiency gains. As of December 2023, over 10,000 pathologists and scientists, including those at leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies, used Proscia's solutions.
Furthermore, in December 2023, CellNetix Pathology & Laboratories announced a collaboration with Proscia to digitize a portion of its 1 million glass slides per year and adopt AI-powered digital pathology workflows.

Proscia

Software that provides a list of possible diseases based on data collected from patients. Platforms are only used for initial assessments.

Platforms and software that generates alerts based on patient treatment and current status.

Platforms and software that monitor and track treatment plans of patients, identifies possible treatment issues, and suggests alternative treatment options.

Workflow management software that helps clinicians track and follow procedure for operations.

Companies that use GenAI as a core part of their product offering for Clinical Decision Support Systems

Uses digital mediums to generate actionable insights from health data

Clinical Decision Support System providers incorporate GenAI to enhance their systems

In most cases, CDSSs are provided to healthcare providers

Uses IoT to connect databases with medical devices for decision support

Uses AI/ML to output decisions/recommended actions based on databases of medical records

Kheiron Medical Technologies

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless